Johnson & Johnson heads into its July 15 earnings release with Polymarket traders pricing a 92% probability of a beat, following four consecutive quarterly beats and raised full-year guidance. First-quarter revenue rose 9.9% to $24.06 billion, driven by an 11.2% jump in Innovative Medicine, while the nearly $9 billion MedTech segment grew 7.7%, providing diversification that peers AbbVie and Pfizer cannot match. Management lifted full-year revenue guidance to between $100.30 billion and $101.30 billion, with adjusted EPS expected at $11.45 to $11.65. The company also plans to separate its DePuy Synthes orthopaedics business, which could further expand its valuation multiple. JNJ has raised its dividend for 64 consecutive years, most recently to $1.34 per share quarterly, backed by $19.7 billion in free cash flow.
Johnson & JohnsonRaised full-year guidance, strong earnings history, and planned orthopaedics separation expected to expand valuation multiple.
AbbVie Inc
Pfizer Inc
NVIDIA Corporation